Literature DB >> 33090181

Socioeconomic Disparities Associated With MGMT Promoter Methylation Testing for Patients With Glioblastoma.

Nayan Lamba1, Ugonma N Chukwueke2, Timothy R Smith3, Keith L Ligon4, Ayal Aizer1, David A Reardon2, J Bryan Iorgulescu4.   

Abstract

Entities:  

Year:  2020        PMID： 33090181      PMCID： PMC7582228          DOI： 10.1001/jamaoncol.2020.4937

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  5 in total

Review 1.  Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Authors:  Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

2.  The influence of race and socioeconomic status on therapeutic clinical trial screening and enrollment.

Authors:  Ramin A Morshed; Sheantel J Reihl; Annette M Molinaro; Sofia Kakaizada; Jacob S Young; Jessica D Schulte; Nicholas Butowski; Jennie Taylor; Nancy Ann Bush; Manish K Aghi; Mitchel S Berger; Susan Chang; Jennifer Clarke; Shawn L Hervey-Jumper
Journal:  J Neurooncol       Date:  2020-04-29       Impact factor: 4.130

Review 3.  Barriers to accrual and enrollment in brain tumor trials.

Authors:  Eudocia Q Lee; Ugonma N Chukwueke; Shawn L Hervey-Jumper; John F de Groot; Jose Pablo Leone; Terri S Armstrong; Susan M Chang; David Arons; Kathy Oliver; Kay Verble; Al Musella; Nicole Willmarth; Brian M Alexander; Amanda Bates; Lisa Doherty; Evanthia Galanis; Sarah Gaffey; Thomas Halkin; Bret E Friday; Maryam Fouladi; Nancy U Lin; David Macdonald; Minesh P Mehta; Marta Penas-Prado; Michael A Vogelbaum; Solmaz Sahebjam; David Sandak; Martin van den Bent; Michael Weller; David A Reardon; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2019-09-06       Impact factor: 12.300

4.  The Misclassification of Diffuse Gliomas: Rates and Outcomes.

Authors:  J Bryan Iorgulescu; Matthew Torre; Maya Harary; Timothy R Smith; Ayal A Aizer; David A Reardon; Jill S Barnholtz-Sloan; Arie Perry
Journal:  Clin Cancer Res       Date:  2019-01-11       Impact factor: 12.531

5.  MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.

Authors:  Alireza Mansouri; Laureen D Hachem; Sheila Mansouri; Farshad Nassiri; Normand J Laperriere; Daniel Xia; Neal I Lindeman; Patrick Y Wen; Arnab Chakravarti; Minesh P Mehta; Monika E Hegi; Roger Stupp; Kenneth D Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2019-02-14       Impact factor: 12.300
  5 in total
  10 in total

Review 1.  Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment.

Authors:  Samuel S Widodo; Ryan A Hutchinson; Yitong Fang; Stefano Mangiola; Paul J Neeson; Phillip K Darcy; Alexander D Barrow; Christopher M Hovens; Marija Dinevska; Stanley S Stylli; Theo Mantamadiotis
Journal:  Cancer Immunol Immunother       Date:  2021-01-03       Impact factor: 6.968

2.  Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients.

Authors:  Vasileios K Kavouridis; Keith L Ligon; Patrick Y Wen; J Bryan Iorgulescu
Journal:  J Neurooncol       Date:  2022-04-26       Impact factor: 4.130

3.  The epidemiology of primary and metastatic brain tumors in infancy through childhood.

Authors:  Nayan Lamba; Andrew Groves; Matthew Torre; Kee Kiat Yeo; J Bryan Iorgulescu
Journal:  J Neurooncol       Date:  2022-01-17       Impact factor: 4.130

4.  Underutilization of Guideline-Recommended Mismatch Repair/Microsatellite Instability Biomarker Testing in Advanced Colorectal Cancer.

Authors:  David J Papke; Neal I Lindeman; Deborah Schrag; J Bryan Iorgulescu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-09-02       Impact factor: 4.090

5.  Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.

Authors:  Mary Jane Lim-Fat; Gilbert C Youssef; Mehdi Touat; J Bryan Iorgulescu; Sydney Whorral; Marie Allen; Rifaquat Rahman; Ugonma Chukwueke; J Ricardo McFaline-Figueroa; Lakshmi Nayak; Eudocia Q Lee; Tracy T Batchelor; Omar Arnaout; Pier Paolo Peruzzi; E Antonio Chiocca; David A Reardon; David Meredith; Sandro Santagata; Rameen Beroukhim; Wenya Linda Bi; Keith L Ligon; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2022-07-01       Impact factor: 13.029

6.  High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient.

Authors:  Elena Anghileri; Natalia Di Ianni; Rosina Paterra; Tiziana Langella; Junfei Zhao; Marica Eoli; Monica Patanè; Bianca Pollo; Valeria Cuccarini; Antonio Iavarone; Raul Rabadan; Gaetano Finocchiaro; Serena Pellegatta
Journal:  Cancer Immunol Immunother       Date:  2020-11-03       Impact factor: 6.968

7.  Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma.

Authors:  Mary Jane Lim-Fat; Kun Wei Song; J Bryan Iorgulescu; Brian M Andersen; Deborah A Forst; Justin T Jordan; Elizabeth R Gerstner; David A Reardon; Patrick Y Wen; Isabel Arrillaga-Romany
Journal:  J Neurooncol       Date:  2021-03-01       Impact factor: 4.130

8.  Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database.

Authors:  Jad Zreik; Panagiotis Kerezoudis; Mohammed Ali Alvi; Yagiz U Yolcu; Sani H Kizilbash
Journal:  Front Oncol       Date:  2021-11-09       Impact factor: 6.244

9.  Exploration and functionalization of M1-macrophage extracellular vesicles for effective accumulation in glioblastoma and strong synergistic therapeutic effects.

Authors:  Xiaojun Wang; Hui Ding; Zongyang Li; Yaonan Peng; Hui Tan; Changlong Wang; Guodong Huang; Weiping Li; Guanghui Ma; Wei Wei
Journal:  Signal Transduct Target Ther       Date:  2022-03-16

10.  METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m6A Dependent Manner.

Authors:  Jia Shi; Gang Chen; Xuchen Dong; Haoran Li; Suwen Li; Shan Cheng; Yongdong Li; Liping Wang; Jiaqi Yuan; Zhiyuan Qian; Jun Dong
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.